Melanotan I (Afamelanotide)
Melanocortin · By Preptide Pro editorial team · Last updated
Melanotan I (Afamelanotide) is a melanocortin peptide, and it has an FDA-approved product. A synthetic alpha-MSH analogue. Approved by the FDA as an implant for erythropoietic protoporphyria.
FDA-approved (see products)Chemistry (PubChem)
| PubChem CID | 16197727 |
|---|---|
| CAS number | 75921-69-6 |
| Molecular formula | C78H111N21O19 |
| Molecular weight | 1646.8 g/mol |
| Other names | Afamelanotide, Melanotan, 4-Norleucyl-7-phenylalanine-alpha-msh, NDPMSH, (Nle(4),D-Phe(7))alpha-MSH, RefChem:57383, D02BB02, DTXCID70149334 |
Is Melanotan I (Afamelanotide) FDA-approved?
| Brand | Application | Status | Sponsor |
|---|---|---|---|
| SCENESSE | NDA210797 | Prescription | CLIVUNEL INC |
How much research is there on Melanotan I (Afamelanotide)?
PubMed lists 119 records for “afamelanotide”, of which 10 are tagged as human clinical trials.
| Recent study | Journal | Date |
|---|---|---|
| Acute impact of afamelanotide on UVR erythemal and melanogenic responses in healthy humans in vivo: an exploratory study. | Photochem Photobiol Sci | 2026 Nov |
| Adjunctive use of Polypodium leucotomos extract in patients with erythropoietic protoporphyria: An exploratory study. | Photochem Photobiol | 2026 Sep-Oct |
| Heterochiral co-assembly of β-strands and hairpins affords stereocomplexed peptide hydrogels for drug delivery. | J Control Release | 2026 Jul 10 |
| A Review of Randomized Controlled Trials for Vitiligo Therapies Published Between 2013 and 2023. | Cureus | 2026 Jul |
| Investigation of the stability profile of therapeutic α-MSH analogue: Insights from liquid chromatography-high resolution mass spectrometry analysis of afamelanotide. | J Pharm Biomed Anal | 2026 May 15 |
Sources
This is general research information, not medical advice. Check with a clinician before using any compound.